Please use this identifier to cite or link to this item: https://doi.org/10.1080/21645515.2016.1178433
DC FieldValue
dc.titleThe value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries
dc.contributor.authorHoward, N
dc.contributor.authorMounier-Jack, S
dc.contributor.authorGallagher, KE
dc.contributor.authorKabakama, S
dc.contributor.authorGriffiths, UK
dc.contributor.authorFeletto, M
dc.contributor.authorLaMontagne, DS
dc.contributor.authorBurchett, HED
dc.contributor.authorWatson-Jones, D
dc.date.accessioned2021-11-02T05:31:09Z
dc.date.available2021-11-02T05:31:09Z
dc.date.issued2016-01-01
dc.identifier.citationHoward, N, Mounier-Jack, S, Gallagher, KE, Kabakama, S, Griffiths, UK, Feletto, M, LaMontagne, DS, Burchett, HED, Watson-Jones, D (2016-01-01). The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries. HUMAN VACCINES & IMMUNOTHERAPEUTICS 12 (9) : 2475-2477. ScholarBank@NUS Repository. https://doi.org/10.1080/21645515.2016.1178433
dc.identifier.isbn2164554X
dc.identifier.issn21645515
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/205456
dc.description.abstractDemonstration projects or pilots of new public health interventions aim to build learning and capacity to inform country-wide implementation. Authors examined the value of HPV vaccination demonstration projects and initial national programmes in low-income and lower-middle-income countries, including potential drawbacks and how value for national scale-up might be increased. Data from a systematic review and key informant interviews, analyzed thematically, included 55 demonstration projects and 8 national programmes implemented between 2007-2015 (89 years' experience). Initial demonstration projects quickly provided consistent lessons. Value would increase if projects were designed to inform sustainable national scale-up. Well-designed projects can test multiple delivery strategies, implementation for challenging areas and populations, and integration with national systems. Introduction of vaccines or other health interventions, particularly those involving new target groups or delivery strategies, needs flexible funding approaches to address specific questions of scalability and sustainability, including learning lessons through phased national expansion.
dc.language.isoen
dc.publisherTAYLOR & FRANCIS INC
dc.sourceElements
dc.subjectdemonstration projects
dc.subjectHPV
dc.subjectlow and middle-income countries
dc.subjectPapillomavirus
dc.subjectvaccination
dc.typeArticle
dc.date.updated2021-10-30T09:48:32Z
dc.contributor.departmentSAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
dc.description.doi10.1080/21645515.2016.1178433
dc.description.sourcetitleHUMAN VACCINES & IMMUNOTHERAPEUTICS
dc.description.volume12
dc.description.issue9
dc.description.page2475-2477
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
The value of demonstration projects for new interventions The case of human papillomavirus vaccine introduction in low- and .pdfPublished version307.23 kBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.